Clinical Significance of Drug-related Gene Detection in Patients with Acute Ischemic Stroke Treated with Double-antibody Therapy
Objective:To explore the clinical significance of drug-related gene detection in dual antiplatelet therapy(aspirin+clopidogrel)in patients with acute ischemic stroke(AIS).Methods:A total of 100 AIS patients admitted to our hospital from April 2021 to April 2023 were randomly divided into control group and observation group,with 50 patients in each group.The control group selected the medication recommended method in the current AIS guidelines for treatment,and the observation group was treated with the recommended drug after genetic polymorphism testing.The treatment effect and medication safety of the two groups were evaluated,and the recurrence within 3 months and 6 months of follow-up was recorded.Results:The effective rate of treatment in the observation group was 92.00%,which was higher than 76.00%in the control group(P<0.05).The overall incidence of systemic hemorrhagic events during medication in the observation group was 8.00%,which was lower than 24.00%in the control group(P<0.05).The recurrence rates in the observation group were 0 and 2.00%,respectively,which were lower than 12.00%and 16.00%in the control group(P<0.05).Conclusion:Through drug-related gene detection to guide the individualized medication of double-antibody therapy in AIS patients,it can effectively improve the effect of anti-platelet aggregation therapy,reduce the recurrence rate,and have a high safety factor.
NETL
NSTL
万方数据
